gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Cerebrospinal fluid (CSF) : Transthyretin as protein marker for Moyamoya disease

Liquor cerebrospinals (CSF): Transthyretin als Proteinmarker bei Moyamoya Erkrankung

Meeting Abstract

  • corresponding author P. Horn - Klinik für Neurochirurgie, Universitätsklinikum Mannheim
  • S. Rueggeberg - Proteomic Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg
  • P. Schmiedek - Klinik für Neurochirurgie, Universitätsklinikum Mannheim
  • T. Franz - Proteomic Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg
  • P. Vajkoczy - Klinik für Neurochirurgie, Universitätsklinikum Mannheim

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. DocP073

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2005/05dgnc0341.shtml

Veröffentlicht: 4. Mai 2005

© 2005 Horn et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Moyamoya disease (MMD) is a rare entity that results in progressive occlusion of the arteries of the circle of Willis. Although the cause of MMD remains undetermined, evidence supports infectious and auto-immun relateded origin, suggesting humorally mediated initiation of MMD. In order to further elucidate these findings, proteome analysis of cerebrospinal fluid (CSF) was performed in patients with MMD.

Methods

Thirty patients (22 adults [19 female, 3 male]; 8 children [5 female, 3 male]) with confirmed MMD and 10 patients (2 female, 8 male) with atherosclerotic steno-occlusive disease who served as controls were enrolled in the present study. Pooled and individual CSF samples were analyzed using a 2-D gel-electrophoresis approach. Abundant proteins, albumin and immunoglobulines, were removed prior to ioselectric focusing. Fluorescent gel stain was used to do a differential proteome analysis with concurrent in-gel protein quantitation.

Results

Ten differentially expressed proteins were excised followed by in-gel digestion and peptide sequencing by tandem mass spectrometry (MS). One Protein, a mutated Transthyretin, was present in 71% of all MMD patients regardless their sex and age and in 80% of the adult patients, whereas it was not found in control persons. The performed Nano ESI (Electrospray-imaging)- MS/ MS sequence analysis of the Transthyretin revealed a specific post-translational modification of glutaric acid at postion 61.

Conclusions

Transthyretin can be used as a specific, but not quantitative disease marker for MMD.